About Steen Bjerre

This author has not yet filled in any details.
So far Steen Bjerre has created 126 blog entries.

Attune Announces Positive Data from Pre-Clinical Studies


  Attune Pharmaceuticals announces positive results from preclinical safety studies evaluating ATN-249, a novel orally administered plasma kallikrein inhibitor for the treatment of HAE. The strong safety, high potency, and high selectivity results suggest a wide therapeutic window with once-daily dosing potential of ATN-249. In the preclinical toxicology and safety pharmacology studies, ATN-249 was generally [...]

Lanadelumab Reduces HAE Monthly Attack Rate by 87 %


Shire plc announces positive topline Phase 3 results for the HELP study, a global, multi-center, randomized, double-blind placebo-controlled parallel group trial that evaluated the efficacy and safety of subcutaneously administered lanadelumab versus placebo over 26 weeks in patients 12 years of age or older with HAE. Lanadelumab is an investigational treatment being evaluated for the [...]

2018 HAE Global Conference will take place in Vienna, Austria


Following the very successful HAE conferences in Copenhagen, Denmark in 2012, Washington D.C., USA in 2014, and Madrid, Spain in 2016, HAEi is delighted to announce that the fourth HAE Global Conference will be held in Vienna, Austria in May 2018. Once again HAEi welcomes HAE patients, caregivers, healthcare professionals, and industry representatives to a [...]

Adverum Reports First Quarter 2017 Financial Results


Adverum Biotechnologies, Inc. has reported the financial results for the first quarter ended March 31, 2017. “Adverum is well positioned in the gene therapy space with a robust pipeline and a platform of industry-leading AAV vector technology, including novel vector development capabilities,” said Amber Salzman, Ph.D., president and CEO of Adverum Biotechnologies. “Our strong cash [...]

BioCryst Reports First Quarter 2017 Financial Results


BioCryst Pharmaceuticals, Inc. has announced the financial results for the first quarter ended March 31, 2017. "We have completed enrollment in Part 1 and 2 of the APeX-1 Phase 2 clinical trial of BCX7353 for prevention of angioedema attacks and will report top-line data in the second quarter of 2017 as planned," said Jon P. [...]

Shire delivers strong Q1 2017 revenue growth


Shire plc has announced the unaudited results for the three months ended March 31, 2017. Flemming Ornskov, Shire CEO, commented: "In the first quarter we delivered strong top-line growth. (...) Our priorities for the rest of 2017 remain unchanged: launching new products while driving commercial excellence, generating operational efficiencies, and advancing our pipeline of novel therapies. [...]

Raising awareness step by step on the Camino


30 people – most of them suffering from a rare and potentially fatal disease – will meet mid-May in northern Spain in order to walk part of the legendary Camino de Santiago together. The patients all suffer from Hereditary Angioedema (HAE) and it is far from an everyday occurrence to walk the kind of mileage [...]

BioCryst Expands Development to Explore Treatment of Acute HAE Attacks


BioCryst Pharmaceuticals, Inc. plans to explore a new oral liquid formulation of BCX7353 for the treatment of acute attacks in patients with HAE. The company has received initial regulatory approvals in Europe to initiate the ZENITH-1 exploratory clinical trial this summer. "To complement the attractive profile of our prophylactic treatment program, as evidenced by the [...]

Japan Approves Berinert for Short-Term Prophylaxis


As of 24 March 2017, Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved an extended use of Berinert from CSL Behring, a C1-esterase inhibitor (C1-INH) concentrate, for pre-procedure prevention (short-term prophylaxis) of acute episodes of HAE . Berinert is now indicated for the treatment of acute episodes and for pre-procedure prevention (short-term prophylaxis) of acute [...]

Pivotal Phase III Data for CSL Behring’s Subcutaneous C1-Esterase Inhibitor


New England Journal of Medicine (NEJM) has published results from the COMPACT study, a pivotal Phase III study evaluating the safety and efficacy of CSL830 (a novel, investigational, self-administered, subcutaneous C1-Esterase Inhibitor [C1-INH] Human replacement therapy) from CSL Behring. The study met its primary efficacy endpoint, significantly reducing the time-normalized number of HAE attacks. In [...]